Clinical Trial Search

Primary: Exclusive Breast Feeding Rate at Six Weeks Postnatal Age — 271; 117; 97 Participants

Primary: Mean Ocular Itching at Onset of Action — 0.4; 1.9; 0.4; 0.6 Units on a scale

Primary: Level of Pain/Heat in the Lower Extremities Scored by the Participants on the Visual Analog Scale (VAS) Following Intra-arterial Administration of ISOVUE-250 or…

Primary: Six Month Blood Levels of Homocysteine, Glutathione, and the Ratio of Aβ42 to Aβ40 (as a Percent of Baseline Levels) After Daily Intake of Cerefolin NAC Plus a…

Primary: Gracely Box Intensity Rating Scale — 13.18; 14.43; 10.64; 13.00 units on a scale

Primary: Pain Measurements Via Numeric Pain Rating Scales (NRS) — 2.67; 1.58; 0.62; 3.67 units on a scale

Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04

Primary: Percentage of Participants With Residual Neuromuscular Blockade (NMB)(Train of Four [TOF] Ratio <0.9) at Time of Tracheal Extubation — 56 percentage of participants

Primary: Change From Baseline in Normalised Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over the 24-h Period After 6 Weeks of Treatment — 0.065; 0.055…

Primary: Knee Score at 2 Years Post Operation — 91; 89 units on a scale

Primary: Change From Baseline to Endpoint in Mean Pain, Scored Daily on a on an 11-point (0-10) Numeric Rating Pain Scale (NRPS), Where 0 = no Pain and 10 = Worst Possible Pain…

Primary: Participants With At Least One Treatment-Emergent Adverse Event (TEAE) — 50 participants

Primary: Natural Logarithm Transformed Serum Intact Fibroblast Growth Factor (FGF-23) Levels at Week 12 Last Observation Carried Forward (LOCF) — 4.0089; 4.1210 pg/ml — p=0.3186

Primary: Seroprotection Rate: Anti-PRP Antibodies — 100; 100 percentage of subjects

Primary: Pain Intensity Score at Day 15 — 6.61 cm